Published in Law and Health Weekly, July 22nd, 2006
This patent reinforces Echelon's leadership position in the phospholipids research space, is the first patent allowance of its kind, and strengthens the oncology synergy within Echelon's parent company, AEterna Zentaris (AEZS).
PI3-K is a key cellular enzyme and is often altered in diseases, leading to abnormal cell growth in cancer and pathological cellular response in inflammation. Considerable research is being done to determine its importance and potential as a target for...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law and Health Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.